在首次发生免疫性血小板减少性紫癜后成功进行mRNA SARS-CoV-2疫苗再次接种。
Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
作者信息
Chanut Mathilde, Jaidi Rym, Kohn Milena, Grange Thomas, Brones Clara, Lombion Naëlle, Rousselot Philippe, Longval Thomas
机构信息
Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
出版信息
Platelets. 2022 May 19;33(4):652-653. doi: 10.1080/09537104.2022.2044463. Epub 2022 Feb 28.
In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine. We present the case of a 73-year-old woman with de novo ITP after a first injection of SARS-Cov-2 mRNA vaccine (Moderna vaccine) who experienced a successful rechallenge of SARS-Cov-2 mRNA vaccine (Pfizer vaccine) a few months later.
2021年，全球经历了规模最大的抗击新冠疫情疫苗接种行动。在接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗后，已报告多例特发性血小板减少症病例。我们报告了一例73岁女性患者，在首次接种SARS-CoV-2 mRNA疫苗（Moderna疫苗）后出现新发免疫性血小板减少性紫癜（ITP），几个月后再次成功接种SARS-CoV-2 mRNA疫苗（辉瑞疫苗）。
Zotero 插件